Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ELTX stock hub

Elicio Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ELTXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

182.3M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ELTX

In the news

Latest news · ELTX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-152.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ELTX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001555192
Company name	Elicio Therapeutics, Inc.
Country	United States
Country code	US
Cusip	28657F103
Employees	33
Employees Change	1%
Employees Change Percent	3.13
Enterprise value	$178.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US28657F1030
Last refreshed	2026-05-10
Market cap	$182.3M
Market cap category	Micro-Cap
Price	$9.91
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	ELTX
Website	https://elicio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-21.71%
FCF yield	-20.28%
P/B ratio	107.83x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-39.6M
Net Income Growth Quarters	2%
Net Income Growth Years	1%
Profit Per Employee	$-1.2M
ROA	-87.24
Roa5y	-90.02
ROCE	-212.4
ROIC	-152.7

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	99.89%
EPS Growth Quarters	2
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$25.9M
Cash	$18.6M
Current Assets	$19.3M
Current Liabilities	$8.1M
Debt	$14.5M
Debt Equity	$8.87
Equity	$1.6M
Interest Coverage	-33.29
Liabilities	$24.2M
Long Term Assets	$6.6M
Long Term Liabilities	$16.1M
Net Cash	$4.1M
Net Cash By Market Cap	$2.22
Net Debt Equity	$-2.48
Tangible Book Value	$1.6M
Tangible Book Value Per Share	$0.09
WACC	11.79

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.38
Net Working Capital	$-6.4M
Quick ratio	2.29
Working Capital	$11.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-25.48%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	99.8%
200-day SMA	9.88
50-day SMA	11.33
50-day SMA vs 200-day SMA	50over200
All Time High	24.39
All Time High Change	-59.37%
All Time High Date	2023-06-02
All Time Low	2.96
All Time Low Change	234.8%
All Time Low Date	2024-02-07
ATR	0.83
Beta	1.45
Beta1y	1.1
Beta2y	0.94
Ch YTD	24.5
High	10.48
High52	14.93
High52 Date	2026-03-02
High52ch	-33.62%
Low	9.85
Low52	4.89
Low52 Date	2025-05-08
Low52ch	102.66%
Ma50ch	-12.53%
Price vs 200-day SMA	0.26%
RSI	38.24
RSI Monthly	51.89
RSI Weekly	49.56
Sharpe ratio	1.24x
Sortino ratio	2.21
Total Return	-25.48%
Tr YTD	24.5
Tr1m	-1.78%
Tr1w	-7.81%
Tr3m	19.11%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.47
Operating Income	$-37.7M
Price target	$18
Price Target Change	$81.64

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	12,712,310%
Float Percent	69.1%
Net Borrowing	9,866,000
Shares Insiders	30.9%
Shares Institutions	13.18%
Shares Out	18,396,074
Shares Qo Q	-7.1%
Shares Yo Y	25.48%
Short Float	11.35%
Short Ratio	13.28
Short Shares	7.84

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-39.7M
Average Volume	126,726.95x
Bv Per Share	0.09
CAPEX	$-16,000
Ch1m	-1.78
Ch1w	-7.81
Ch1y	99.8
Ch3m	19.11
Ch6m	11.73
Change	-1%
Change From Open	-1.88
Close	10.01
Days Gap	0.9
Depreciation Amortization	204,000
Dollar Volume	1,041,323
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-37.7M
EBITDA	$-37.5M
EPS	$-2.58
F Score	3
FCF	$-37M
FCF EV Yield	-20.74x
FCF Per Share	$-2.01
Financing CF	36,695,000
Fiscal Year End	December
Founded	2,011
Investing CF	-16,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-12
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2023-03-17
Ma150	9.64
Ma150ch	2.78%
Ma20	11.3
Ma20ch	-12.29%
Net CF	-225,000
Next Earnings Date	2026-05-22
Open	10.1
Optionable	Yes
Position In Range	9.52
Post Close	9.91
Postmarket Change Percent	2.22
Postmarket Price	$10.13
Ppne	5,077,000
Price Date	2026-05-08
Ptbv Ratio	111.4
Relative Volume	0.83x
Share Based Comp	2,697,000
Tr6m	11.73%
Us State	Massachusetts
Volume	105,078

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ELTX pay a dividend?

Capital-return profile for this ticker.

Performance

ELTX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ELTX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+13.2%

Float: +69.1% of shares outstanding

Insider ownership

+30.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ELTX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.2

Neutral momentum band

Price vs 200-day MA

+0.3%

50/200-day relationship not available

Beta (5Y)

1.45

More volatile than the market

Sharpe ratio

1.24

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ELTX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ELTX stock rating?

Elicio Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ELTX analysis?

The full report lives at /stocks/ELTX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ELTX?

The latest report frames ELTX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ELTX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.